Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 12/20 | 0.49 |
| ▸ | GSK3B | P49841 | 11/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | CLK2 | P49760 | 2/20 | 0.49 |
| ▸ | CLK3 | P49761 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.46 |
| ▸ | TTK | P33981 | 4/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.44 |
| ▸ | INCENP | Q9NQS7 | 2/20 | 0.44 |
| ▸ | ITK | Q08881 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14873417 | 0.91 | DYRK1A (0.49) | DYRK1AGSK3BROCK2NAMPTCLK2 | |
| SCHEMBL15476944 | 0.89 | TTK (0.53) | DYRK1AGSK3BROCK2NAMPTCLK2 | |
| SCHEMBL15477042 | 0.88 | CYP3A4 (0.55) | DYRK1AGSK3BROCK2NAMPTCLK2 | |
| SCHEMBL15476835 | 0.86 | TTK (0.56) | DYRK1AGSK3BROCK2NAMPTCLK2 | |
| SCHEMBL14863506 | 0.83 | DYRK1A (0.51) | DYRK1AGSK3BROCK2NAMPTCLK2 | |
| SCHEMBL14873365 | 0.83 | DYRK1A (0.49) | DYRK1AGSK3BROCK2NAMPTCLK2 | |
| SCHEMBL15476690 | 0.83 | TTK (0.53) | DYRK1AGSK3BROCK2NAMPTCLK2 | |
| SCHEMBL15476688 | 0.83 | TTK (0.53) | DYRK1AGSK3BROCK2NAMPTCLK2 | |
| SCHEMBL14863566 | 0.82 | TTK (0.51) | DYRK1AGSK3BROCK2NAMPTCLK2 | |
| SCHEMBL15476525 | 0.82 | ROCK2 (0.49) | DYRK1AGSK3BROCK2NAMPTCLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2766352-B1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIV HEALTH NETWORK UHN (CA) | 2018-06-06 | — | — | EP | disclosed |
| US-9580390-B2 | Indazole compounds as kinase inhibitors and method of treating cancer with same | UNIVERSITY HEALTH NETWORK (CA) | 2017-02-28 | — | — | US | disclosed |
| US-9580390-B2 | Indazole compounds as kinase inhibitors and method of treating cancer with same | UNIVERSITY HEALTH NETWORK (CA) | 2017-02-28 | — | — | US | disclosed |
| US-20140371202-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2014-12-18 | — | — | US | disclosed |
| US-20140371202-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2014-12-18 | — | — | US | disclosed |
| US-20140051679-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERISTY HEALTH NETWORKS (CA) | 2014-02-20 | — | — | US | disclosed |
| US-20140051679-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERISTY HEALTH NETWORKS (CA) | 2014-02-20 | — | — | US | disclosed |
| WO-2013053051-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2013-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371202-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | PLK4, PLK2, PLK3 | DYRK1A 545/4885GSK3B 237/4885ROCK2 570/4885 |
| US-20140051679-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | MAP3K7, MAP3K1, MAP3K20 | DYRK1A 562/4885GSK3B 389/4885ROCK2 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.